Multiple Myeloma
📧 Sign up to get email alerts when something new happens for Multiple Myeloma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2024-10-24Clinical Trial Update: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma [Phase 3]
Phase 3 trial evaluating efficacy and safety of belantamab mafodotin in combination with bortezomib and dexamethasone versus daratumumab wit…
-
CLINICAL_TRIALS trial_result · 2024-10-21Clinical Trial Update: TMI With HD Mel in ASCT for R/R Multiple Myeloma (BMT-03) [Phase 1]
Phase 1 trial evaluating total marrow irradiation with high-dose melphalan as conditioning for autologous stem cell transplantation in relap…
-
CLINICAL_TRIALS trial_result · 2024-10-16Clinical Trial Update: Study of a New Intravenous Drug, Called S65487, in Patients With Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma or Chronic Lymphocytic Leukemia [Phase 1]
Phase 1 study of the intravenous agent S65487 in relapsed or refractory hematologic cancers (acute myeloid leukemia, non-Hodgkin lymphoma, m…
-
CLINICAL_TRIALS trial_result · 2024-10-15Clinical Trial Update: Managed Access Program for Combination Treatment With Belantamab Mafodotin in Multiple Myeloma
Clinical trial update describing a managed access program for a combination treatment including belantamab mafodotin in multiple myeloma.
-
CLINICAL_TRIALS trial_result · 2024-10-10Clinical Trial Update: A Study of HG146 Capsule in Chinese Subjects with Relapsed and Refractory Multiple Myeloma [Phase 1]
A Phase 1 study of HG146 Capsule in Chinese subjects with relapsed and refractory multiple myeloma has been terminated.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2024-10-09Clinical Trial Update: Effect of Sleep Quality on Hematopoietic Cell Transplant Patient Outcomes [NA]
This clinical trial update notes the termination of a study assessing whether sleep quality affects outcomes after hematopoietic cell transp…
-
CLINICAL_TRIALS trial_result · 2024-10-08Clinical Trial Update: Descartes-08 Consolidation Treatment in Patients With High-Risk Multiple Myeloma High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy [Phase 2]
Phase 2 trial evaluating Descartes-08 consolidation therapy in high-risk multiple myeloma patients with residual disease after induction; th…
-
CLINICAL_TRIALS trial_result · 2024-10-04Clinical Trial Update: Extension of a Study of Allogeneic Hematopoietic Stem Cell Transplantation From One Haplotype Mismatch Related Donor or From an Unrelated Donor to Younger Patients Eligible for Reduced-intensity Conditioning Regimen [Phase 3]
This document reports the completed extension of a Phase 3 study evaluating allogeneic hematopoietic stem cell transplantation from haplotyp…
-
CLINICAL_TRIALS trial_result · 2024-10-03Clinical Trial Update: A Safety, Tolerability and Efficacy Study of ACE-011 in Patients With Osteolytic Lesions of Multiple Myeloma [Phase 2]
Phase 2 study evaluating safety, tolerability, and efficacy of ACE-011 in patients with osteolytic lesions due to multiple myeloma has compl…
-
CLINICAL_TRIALS trial_result · 2024-10-03Clinical Trial Update: Study of the Immune Response After Vaccination in Multiple Myeloma Patients
This document provides an update on a completed clinical trial studying the immune response to vaccination in patients with multiple myeloma…
-
CLINICAL_TRIALS trial_result · 2024-10-03Clinical Trial Update: Providing Cancer Care Closer to Home for Patients With Multiple Myeloma [NA]
The clinical trial NCT05971056 exploring delivery of cancer care closer to home for patients with multiple myeloma has been terminated.
-
CLINICAL_TRIALS trial_result · 2024-10-02Clinical Trial Update: A Study Of TAK-981 Given With Monoclonal Antibodies (mAbs) In Adults With Relapsed or Refractory Multiple Myeloma (RRMM) [Phase 1, Phase 2]
This update reports the termination of a Phase 1/2 trial of TAK-981 in combination with monoclonal antibodies in adults with relapsed or ref…
-
CLINICAL_TRIALS trial_result · 2024-09-27Clinical Trial Update: MAGNETISMM-2: Study of Elranatamab (PF-06863135) in Japanese Participants With Multiple Myeloma [Phase 1]
Phase 1 results update for elranatamab (PF-06863135) in Japanese participants with relapsed or refractory multiple myeloma.
-
CLINICAL_TRIALS trial_result · 2024-09-25Clinical Trial Update: Geriatric-assessment Interventions to Address Functional Deficits in Older Adults w Multiple Myeloma [NA]
This completed clinical trial evaluated geriatric-assessment interventions to address functional deficits in older adults with multiple myel…
-
CLINICAL_TRIALS trial_result · 2024-09-25Clinical Trial Update: Impact of Chemotherapeutic Treatments in Patients Aged 75 Years and Over Treated for Lymphoid Hematological Malignancy [NA]
Completed clinical trial assessing the impact of chemotherapeutic treatments in patients aged 75 and older with lymphoid hematological malig…
-
CLINICAL_TRIALS trial_result · 2024-09-25Clinical Trial Update: Chimeric Antigen Receptor Modified T Cells Targeting BCMA for the Treatment of Relapsed/Refractory Multiple Myeloma [Phase 2]
A Phase 2 clinical trial is evaluating BCMA-targeted CAR-T cells for relapsed/refractory multiple myeloma and is currently recruiting. The t…
-
CLINICAL_TRIALS trial_result · 2024-09-23Clinical Trial Update: Quality of Life the Danish Multiple Myeloma Patients
Completed clinical trial update from Odense University Hospital examining quality of life in Danish patients with multiple myeloma.
-
CLINICAL_TRIALS trial_result · 2024-09-19Clinical Trial Update: WT1 Vaccine Treatment of Patients With Multiple Myeloma After Autologous Stem Cell Transplantation [Phase 1, Phase 2]
Results from a Phase 1/2 study evaluating the WT1 peptide vaccine in patients with multiple myeloma after autologous stem cell transplantati…
-
CLINICAL_TRIALS trial_result · 2024-09-19Clinical Trial Update: A Study to Determine Dose and Regimen of Durvalumab as Monotherapy or in Combination With Pomalidomide With or Without Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma [Phase 1]
Phase 1 study to determine the dose and regimen of Durvalumab as monotherapy or in combination with Pomalidomide with or without Dexamethaso…
-
CLINICAL_TRIALS trial_result · 2024-09-19Clinical Trial Update: A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma. [Phase 2]
Pfizer completed a Phase 2 study of elranatamab (PF-06863135) in Chinese participants with refractory/relapsed multiple myeloma, with result…
-
CLINICAL_TRIALS trial_result · 2024-09-19Clinical Trial Update: Carfilzomib With Bendamustine and Dexamethasone in Multiple Myeloma [Phase 1, Phase 2]
Phase 1/2 trial of carfilzomib with bendamustine and dexamethasone in multiple myeloma has been terminated; results have been posted.
-
CLINICAL_TRIALS trial_result · 2024-09-04Clinical Trial Update: Pembrolizumab and Radiation Therapy in Patients With Relapsed or Refractory Multiple Myeloma [Phase 1, Phase 2]
A completed Phase 1/2 trial evaluating pembrolizumab in combination with radiation therapy for relapsed or refractory multiple myeloma; resu…
-
CLINICAL_TRIALS trial_result · 2024-09-03Clinical Trial Update: A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma [Phase 1]
Pfizer's Phase 1 trial of Maplirpacept (PF-07901801) in advanced hematologic malignancies, including diffuse large B-cell lymphoma, acute my…
-
CLINICAL_TRIALS trial_result · 2024-08-30Clinical Trial Update: A Study of CC-99712, a BCMA Antibody-Drug Conjugate, in Participants With Relapsed and Refractory Multiple Myeloma [Phase 1]
Phase 1 study of CC-99712, a BCMA-directed antibody-drug conjugate, in relapsed and refractory multiple myeloma has been terminated.
-
CLINICAL_TRIALS trial_result · 2024-08-27Clinical Trial Update: A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants With Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants With Solid Tumors on PD1/PDL1 Inhibitor Therapy [Phase 2]
This Phase 2 trial assesses the safety and immunogenicity of the Moderna COVID-19 vaccine (mRNA-1273) in patients with solid tumors and hema…